STOCK TITAN

[6-K] Grupo Cibest S.A. American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Intuitive Surgical 10-Q (Q2 2025) highlights

  • Revenue: $2.44 bn, +21% YoY; six-month sales $4.69 bn, +20%.
  • Profitability: Gross profit $1.62 bn (66.3% margin, −200 bps YoY); operating income $743 m, +31%; net income attributable $658 m, +25%; diluted EPS $1.81, +24%.
  • Cash flow & liquidity: H1 operating cash flow $1.30 bn, +46%; cash, cash equivalents & investments now $9.53 bn (up $0.70 bn from YE-24); net cash positive balance sheet with equity covering 89% of assets.
  • Capital deployment: Repurchased 0.3 m shares for $181 m; new $4 bn authorization leaves $3.8 bn available.
  • Segment trends: Instruments & accessories +18%, Systems +28%, Service +23%. U.S. revenue +24%, OUS +17%.
  • Costs: SG&A +7%; R&D +12%; share-based comp $390 m YTD.
  • Balance-sheet movements: Inventory +12% to $1.67 bn; goodwill steady at $349 m. No debt disclosed; contingent liabilities tied to product liability and antitrust cases.
  • Tax: Q2 effective rate 20.2% vs 18.8% prior; H1 rate 8.8% aided by equity-tax benefits.

Takeaway: Robust procedure demand propelled 20%+ growth and stronger operating leverage, while cash generation funds an enlarged buyback; margin compression from mix and spending warrants monitoring.

Principali dati del 10-Q di Intuitive Surgical (Q2 2025)

  • Ricavi: 2,44 mld $, +21% su base annua; vendite semestrali 4,69 mld $, +20%.
  • Redditività: Utile lordo 1,62 mld $ (margine 66,3%, -200 punti base anno su anno); reddito operativo 743 mln $, +31%; utile netto attribuibile 658 mln $, +25%; EPS diluito 1,81 $, +24%.
  • Flusso di cassa e liquidità: Flusso operativo H1 1,30 mld $, +46%; liquidità, equivalenti e investimenti a 9,53 mld $ (in aumento di 0,70 mld $ rispetto a fine 2024); bilancio netto positivo con patrimonio netto che copre l'89% delle attività.
  • Impiego del capitale: Riacquistate 0,3 mln azioni per 181 mln $; nuova autorizzazione da 4 mld $ con 3,8 mld $ ancora disponibili.
  • Tendenze per segmento: Strumenti e accessori +18%, Sistemi +28%, Servizi +23%. Ricavi USA +24%, fuori USA +17%.
  • Costi: SG&A +7%; R&D +12%; compensi basati su azioni 390 mln $ da inizio anno.
  • Movimenti di bilancio: Inventario +12% a 1,67 mld $; avviamento stabile a 349 mln $. Nessun debito segnalato; passività potenziali legate a cause per responsabilità di prodotto e antitrust.
  • Imposte: Aliquota effettiva Q2 al 20,2% vs 18,8% precedente; aliquota H1 all'8,8% favorita da benefici fiscali su azioni.

Conclusione: La forte domanda di procedure ha guidato una crescita superiore al 20% e un migliore leverage operativo, mentre la generazione di cassa finanzia un programma di riacquisto ampliato; la compressione dei margini dovuta al mix e alle spese richiede attenzione.

Aspectos destacados del 10-Q de Intuitive Surgical (Q2 2025)

  • Ingresos: 2,44 mil millones de dólares, +21% interanual; ventas en seis meses 4,69 mil millones, +20%.
  • Rentabilidad: Beneficio bruto de 1,62 mil millones de dólares (margen 66,3%, −200 puntos básicos interanual); ingreso operativo 743 millones, +31%; ingreso neto atribuible 658 millones, +25%; BPA diluido 1,81 $, +24%.
  • Flujo de caja y liquidez: Flujo operativo en H1 1,30 mil millones, +46%; efectivo, equivalentes y inversiones ahora 9,53 mil millones (incremento de 0,70 mil millones desde fin de 2024); balance neto positivo con patrimonio que cubre el 89% de los activos.
  • Despliegue de capital: Recompró 0,3 millones de acciones por 181 millones; nueva autorización de 4 mil millones con 3,8 mil millones disponibles.
  • Tendencias por segmento: Instrumentos y accesorios +18%, Sistemas +28%, Servicios +23%. Ingresos EE.UU. +24%, fuera de EE.UU. +17%.
  • Costos: SG&A +7%; I+D +12%; compensación basada en acciones 390 millones en lo que va del año.
  • Movimientos en el balance: Inventario +12% a 1,67 mil millones; plusvalía estable en 349 millones. Sin deuda reportada; pasivos contingentes vinculados a demandas por responsabilidad de productos y casos antimonopolio.
  • Impuestos: Tasa efectiva Q2 20,2% vs 18,8% previa; tasa H1 8,8% beneficiada por ventajas fiscales sobre acciones.

Conclusión: La sólida demanda de procedimientos impulsó un crecimiento superior al 20% y un mejor apalancamiento operativo, mientras la generación de efectivo financia una recompra ampliada; la compresión de márgenes por mezcla y gastos merece seguimiento.

Intuitive Surgical 10-Q (2025년 2분기) 주요 내용

  • 매출: 24억 4천만 달러, 전년 대비 21% 증가; 상반기 매출 46억 9천만 달러, 20% 증가.
  • 수익성: 총이익 16억 2천만 달러(마진 66.3%, 전년 대비 200bp 감소); 영업이익 7억 4,300만 달러, 31% 증가; 귀속 순이익 6억 5,800만 달러, 25% 증가; 희석 주당순이익 1.81달러, 24% 증가.
  • 현금 흐름 및 유동성: 상반기 영업현금흐름 13억 달러, 46% 증가; 현금 및 현금성 자산과 투자금 95억 3천만 달러(2024년 말 대비 7천만 달러 증가); 순현금 긍정적이며 자산의 89%를 자기자본으로 커버.
  • 자본 배분: 30만 주를 1억 8,100만 달러에 재매입; 40억 달러 신규 승인으로 38억 달러 사용 가능.
  • 사업 부문 동향: 기기 및 액세서리 +18%, 시스템 +28%, 서비스 +23%. 미국 매출 +24%, 해외 매출 +17%.
  • 비용: 판매관리비 +7%; 연구개발비 +12%; 연초부터 주식 기반 보상 3억 9천만 달러.
  • 대차대조표 변동: 재고 +12% 16억 7천만 달러; 영업권 3억 4,900만 달러로 유지. 부채 없음 보고; 제품 책임 및 독점금지 소송 관련 우발부채 존재.
  • 세금: 2분기 실효세율 20.2%, 이전 18.8%; 상반기 실효세율 8.8%, 주식 관련 세제 혜택 영향.

요약: 견고한 수술 수요가 20% 이상의 성장과 운영 레버리지 강화를 이끌었으며, 현금 창출로 확대된 자사주 매입을 지원; 제품 믹스와 지출로 인한 마진 압박은 주시할 필요가 있음.

Points clés du 10-Q d'Intuitive Surgical (T2 2025)

  • Chiffre d'affaires : 2,44 milliards de dollars, +21% en glissement annuel ; ventes semestrielles 4,69 milliards, +20%.
  • Rentabilité : Bénéfice brut 1,62 milliard de dollars (marge de 66,3%, −200 points de base en glissement annuel) ; résultat opérationnel 743 millions, +31% ; résultat net attribuable 658 millions, +25% ; BPA dilué 1,81 $, +24%.
  • Flux de trésorerie et liquidités : Flux de trésorerie opérationnel H1 1,30 milliard, +46% ; trésorerie, équivalents et investissements à 9,53 milliards (en hausse de 0,70 milliard depuis fin 2024) ; bilan net positif avec capitaux propres couvrant 89% des actifs.
  • Déploiement du capital : Rachat de 0,3 million d'actions pour 181 millions ; nouvelle autorisation de 4 milliards avec 3,8 milliards disponibles.
  • Tendances par segment : Instruments et accessoires +18%, Systèmes +28%, Services +23%. Chiffre d'affaires US +24%, hors US +17%.
  • Coûts : SG&A +7% ; R&D +12% ; rémunération en actions 390 millions depuis le début de l'année.
  • Mouvements du bilan : Stocks +12% à 1,67 milliard ; goodwill stable à 349 millions. Pas de dette déclarée ; passifs éventuels liés à des litiges en responsabilité produit et antitrust.
  • Impôts : Taux effectif T2 20,2% contre 18,8% précédemment ; taux H1 8,8% aidé par des avantages fiscaux liés aux actions.

Conclusion : Une forte demande de procédures a propulsé une croissance de plus de 20% et un effet de levier opérationnel renforcé, tandis que la génération de trésorerie finance un programme de rachat élargi ; la compression des marges due au mix produit et aux dépenses mérite une surveillance.

Intuitive Surgical 10-Q Highlights (Q2 2025)

  • Umsatz: 2,44 Mrd. $, +21% gegenüber Vorjahr; Halbjahresumsatz 4,69 Mrd. $, +20%.
  • Profitabilität: Bruttogewinn 1,62 Mrd. $ (Marge 66,3%, −200 Basispunkte YoY); Betriebsergebnis 743 Mio. $, +31%; dem Konzern zurechenbarer Nettogewinn 658 Mio. $, +25%; verwässertes Ergebnis je Aktie 1,81 $, +24%.
  • Cashflow & Liquidität: Operativer Cashflow H1 1,30 Mrd. $, +46%; Zahlungsmittel, Zahlungsmitteläquivalente & Investitionen 9,53 Mrd. $ (plus 0,70 Mrd. $ seit Jahresende 2024); Nettogeldpositive Bilanz mit Eigenkapital, das 89% der Vermögenswerte abdeckt.
  • Kapitalverwendung: 0,3 Mio. Aktien für 181 Mio. $ zurückgekauft; neue 4 Mrd. $-Genehmigung, davon 3,8 Mrd. $ verfügbar.
  • Sektoren-Trends: Instrumente & Zubehör +18%, Systeme +28%, Service +23%. US-Umsatz +24%, außerhalb der USA +17%.
  • Kosten: SG&A +7%; F&E +12%; aktienbasierte Vergütung 390 Mio. $ seit Jahresbeginn.
  • Bilanzbewegungen: Inventar +12% auf 1,67 Mrd. $; Firmenwert stabil bei 349 Mio. $. Keine Schulden ausgewiesen; Eventualverbindlichkeiten im Zusammenhang mit Produkthaftungs- und Kartellverfahren.
  • Steuern: Effektiver Steuersatz Q2 20,2% vs. 18,8% zuvor; H1-Satz 8,8%, begünstigt durch Eigenkapitalsteuer-Vorteile.

Fazit: Starke Verfahrensnachfrage trieb über 20% Wachstum und verbesserte operative Hebelwirkung, während die Cash-Generierung einen erweiterten Aktienrückkauf finanziert; Margendruck durch Produktmix und Ausgaben erfordert Beobachtung.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Double-digit growth, strong cash, mild margin squeeze—overall bullish.

Q2 revenue and EPS beat typical street run-rates (≈15% expected) with 21%/24% gains, signaling sustained procedure momentum across da Vinci and Ion lines. Operating leverage improved (op-margin +220 bps to 30.5%), offsetting a 200 bp gross margin dip from higher service and leasing mix. $9.5 bn liquidity and zero debt provide strategic optionality; new €290 m distributor acquisition won’t strain cash. Expanded $4 bn repurchase plan (≈6% of mkt-cap) is accretive. Litigation disclosures unchanged; accruals suggest contained risk. Inventory build likely anticipates 2H system installs but bears watching. Overall, fundamentals support premium valuation.

TL;DR: Growth solid; watch gross margin slide and rising inventories.

While revenue outperformance is clear, gross margin slipped to 66.3% amid leasing mix and FX. Inventory up $180 m (+12%) could expose company if demand moderates. OpEx discipline tempered, yet share-based comp remains hefty (8% of sales). Regulatory/tariff commentary flags cost headwinds; multiple antitrust suits remain unresolved. Nonetheless, cash flow strength and diversified revenue (42% recurring) mitigate downside. Net impact positive but monitor margin trajectory.

Principali dati del 10-Q di Intuitive Surgical (Q2 2025)

  • Ricavi: 2,44 mld $, +21% su base annua; vendite semestrali 4,69 mld $, +20%.
  • Redditività: Utile lordo 1,62 mld $ (margine 66,3%, -200 punti base anno su anno); reddito operativo 743 mln $, +31%; utile netto attribuibile 658 mln $, +25%; EPS diluito 1,81 $, +24%.
  • Flusso di cassa e liquidità: Flusso operativo H1 1,30 mld $, +46%; liquidità, equivalenti e investimenti a 9,53 mld $ (in aumento di 0,70 mld $ rispetto a fine 2024); bilancio netto positivo con patrimonio netto che copre l'89% delle attività.
  • Impiego del capitale: Riacquistate 0,3 mln azioni per 181 mln $; nuova autorizzazione da 4 mld $ con 3,8 mld $ ancora disponibili.
  • Tendenze per segmento: Strumenti e accessori +18%, Sistemi +28%, Servizi +23%. Ricavi USA +24%, fuori USA +17%.
  • Costi: SG&A +7%; R&D +12%; compensi basati su azioni 390 mln $ da inizio anno.
  • Movimenti di bilancio: Inventario +12% a 1,67 mld $; avviamento stabile a 349 mln $. Nessun debito segnalato; passività potenziali legate a cause per responsabilità di prodotto e antitrust.
  • Imposte: Aliquota effettiva Q2 al 20,2% vs 18,8% precedente; aliquota H1 all'8,8% favorita da benefici fiscali su azioni.

Conclusione: La forte domanda di procedure ha guidato una crescita superiore al 20% e un migliore leverage operativo, mentre la generazione di cassa finanzia un programma di riacquisto ampliato; la compressione dei margini dovuta al mix e alle spese richiede attenzione.

Aspectos destacados del 10-Q de Intuitive Surgical (Q2 2025)

  • Ingresos: 2,44 mil millones de dólares, +21% interanual; ventas en seis meses 4,69 mil millones, +20%.
  • Rentabilidad: Beneficio bruto de 1,62 mil millones de dólares (margen 66,3%, −200 puntos básicos interanual); ingreso operativo 743 millones, +31%; ingreso neto atribuible 658 millones, +25%; BPA diluido 1,81 $, +24%.
  • Flujo de caja y liquidez: Flujo operativo en H1 1,30 mil millones, +46%; efectivo, equivalentes y inversiones ahora 9,53 mil millones (incremento de 0,70 mil millones desde fin de 2024); balance neto positivo con patrimonio que cubre el 89% de los activos.
  • Despliegue de capital: Recompró 0,3 millones de acciones por 181 millones; nueva autorización de 4 mil millones con 3,8 mil millones disponibles.
  • Tendencias por segmento: Instrumentos y accesorios +18%, Sistemas +28%, Servicios +23%. Ingresos EE.UU. +24%, fuera de EE.UU. +17%.
  • Costos: SG&A +7%; I+D +12%; compensación basada en acciones 390 millones en lo que va del año.
  • Movimientos en el balance: Inventario +12% a 1,67 mil millones; plusvalía estable en 349 millones. Sin deuda reportada; pasivos contingentes vinculados a demandas por responsabilidad de productos y casos antimonopolio.
  • Impuestos: Tasa efectiva Q2 20,2% vs 18,8% previa; tasa H1 8,8% beneficiada por ventajas fiscales sobre acciones.

Conclusión: La sólida demanda de procedimientos impulsó un crecimiento superior al 20% y un mejor apalancamiento operativo, mientras la generación de efectivo financia una recompra ampliada; la compresión de márgenes por mezcla y gastos merece seguimiento.

Intuitive Surgical 10-Q (2025년 2분기) 주요 내용

  • 매출: 24억 4천만 달러, 전년 대비 21% 증가; 상반기 매출 46억 9천만 달러, 20% 증가.
  • 수익성: 총이익 16억 2천만 달러(마진 66.3%, 전년 대비 200bp 감소); 영업이익 7억 4,300만 달러, 31% 증가; 귀속 순이익 6억 5,800만 달러, 25% 증가; 희석 주당순이익 1.81달러, 24% 증가.
  • 현금 흐름 및 유동성: 상반기 영업현금흐름 13억 달러, 46% 증가; 현금 및 현금성 자산과 투자금 95억 3천만 달러(2024년 말 대비 7천만 달러 증가); 순현금 긍정적이며 자산의 89%를 자기자본으로 커버.
  • 자본 배분: 30만 주를 1억 8,100만 달러에 재매입; 40억 달러 신규 승인으로 38억 달러 사용 가능.
  • 사업 부문 동향: 기기 및 액세서리 +18%, 시스템 +28%, 서비스 +23%. 미국 매출 +24%, 해외 매출 +17%.
  • 비용: 판매관리비 +7%; 연구개발비 +12%; 연초부터 주식 기반 보상 3억 9천만 달러.
  • 대차대조표 변동: 재고 +12% 16억 7천만 달러; 영업권 3억 4,900만 달러로 유지. 부채 없음 보고; 제품 책임 및 독점금지 소송 관련 우발부채 존재.
  • 세금: 2분기 실효세율 20.2%, 이전 18.8%; 상반기 실효세율 8.8%, 주식 관련 세제 혜택 영향.

요약: 견고한 수술 수요가 20% 이상의 성장과 운영 레버리지 강화를 이끌었으며, 현금 창출로 확대된 자사주 매입을 지원; 제품 믹스와 지출로 인한 마진 압박은 주시할 필요가 있음.

Points clés du 10-Q d'Intuitive Surgical (T2 2025)

  • Chiffre d'affaires : 2,44 milliards de dollars, +21% en glissement annuel ; ventes semestrielles 4,69 milliards, +20%.
  • Rentabilité : Bénéfice brut 1,62 milliard de dollars (marge de 66,3%, −200 points de base en glissement annuel) ; résultat opérationnel 743 millions, +31% ; résultat net attribuable 658 millions, +25% ; BPA dilué 1,81 $, +24%.
  • Flux de trésorerie et liquidités : Flux de trésorerie opérationnel H1 1,30 milliard, +46% ; trésorerie, équivalents et investissements à 9,53 milliards (en hausse de 0,70 milliard depuis fin 2024) ; bilan net positif avec capitaux propres couvrant 89% des actifs.
  • Déploiement du capital : Rachat de 0,3 million d'actions pour 181 millions ; nouvelle autorisation de 4 milliards avec 3,8 milliards disponibles.
  • Tendances par segment : Instruments et accessoires +18%, Systèmes +28%, Services +23%. Chiffre d'affaires US +24%, hors US +17%.
  • Coûts : SG&A +7% ; R&D +12% ; rémunération en actions 390 millions depuis le début de l'année.
  • Mouvements du bilan : Stocks +12% à 1,67 milliard ; goodwill stable à 349 millions. Pas de dette déclarée ; passifs éventuels liés à des litiges en responsabilité produit et antitrust.
  • Impôts : Taux effectif T2 20,2% contre 18,8% précédemment ; taux H1 8,8% aidé par des avantages fiscaux liés aux actions.

Conclusion : Une forte demande de procédures a propulsé une croissance de plus de 20% et un effet de levier opérationnel renforcé, tandis que la génération de trésorerie finance un programme de rachat élargi ; la compression des marges due au mix produit et aux dépenses mérite une surveillance.

Intuitive Surgical 10-Q Highlights (Q2 2025)

  • Umsatz: 2,44 Mrd. $, +21% gegenüber Vorjahr; Halbjahresumsatz 4,69 Mrd. $, +20%.
  • Profitabilität: Bruttogewinn 1,62 Mrd. $ (Marge 66,3%, −200 Basispunkte YoY); Betriebsergebnis 743 Mio. $, +31%; dem Konzern zurechenbarer Nettogewinn 658 Mio. $, +25%; verwässertes Ergebnis je Aktie 1,81 $, +24%.
  • Cashflow & Liquidität: Operativer Cashflow H1 1,30 Mrd. $, +46%; Zahlungsmittel, Zahlungsmitteläquivalente & Investitionen 9,53 Mrd. $ (plus 0,70 Mrd. $ seit Jahresende 2024); Nettogeldpositive Bilanz mit Eigenkapital, das 89% der Vermögenswerte abdeckt.
  • Kapitalverwendung: 0,3 Mio. Aktien für 181 Mio. $ zurückgekauft; neue 4 Mrd. $-Genehmigung, davon 3,8 Mrd. $ verfügbar.
  • Sektoren-Trends: Instrumente & Zubehör +18%, Systeme +28%, Service +23%. US-Umsatz +24%, außerhalb der USA +17%.
  • Kosten: SG&A +7%; F&E +12%; aktienbasierte Vergütung 390 Mio. $ seit Jahresbeginn.
  • Bilanzbewegungen: Inventar +12% auf 1,67 Mrd. $; Firmenwert stabil bei 349 Mio. $. Keine Schulden ausgewiesen; Eventualverbindlichkeiten im Zusammenhang mit Produkthaftungs- und Kartellverfahren.
  • Steuern: Effektiver Steuersatz Q2 20,2% vs. 18,8% zuvor; H1-Satz 8,8%, begünstigt durch Eigenkapitalsteuer-Vorteile.

Fazit: Starke Verfahrensnachfrage trieb über 20% Wachstum und verbesserte operative Hebelwirkung, während die Cash-Generierung einen erweiterten Aktienrückkauf finanziert; Margendruck durch Produktmix und Ausgaben erfordert Beobachtung.

gc_logotipoxnegroxvertical.jpg




UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


--------------------

FORM 6-K
--------------------


REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934


For the month of July, 2025

Commission File Number 001-42656



--------------------

Grupo Cibest S.A.
(Translation of registrant’s name into English)

--------------------


Cra. 48 # 26-85
Medellín, Colombia
(Address of principal executive offices)

--------------------


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ
Form 40-F o
1

gc_logotipoxnegroxvertical.jpg



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Grupo CIBEST S.A.
(Registrant)
Date July, 23, 2025By:/s/ MAURICIO BOTERO WOLFF.
Name:Mauricio Botero Wolff
Title:Vice President of Strategy and Finance



July 23, 2025
Medellin, Colombia

GRUPO CIBEST S.A. ANNOUNCES DECISIONS OF ITS BOARD OF DIRECTORS

The Board of Directors of Grupo Cibest S.A. (“Grupo Cibest”) unanimously authorized Rodrigo Prieto Uribe, the company’s Risk Vicepresident to liquidate 63,736 of his units in the institutional investment fund managed by Protección S.A. (“Protección”), whose investment is primarily composed of Grupo Cibest shares.

Relatedly, the Board of Directors unanimously authorized Rodrigo Prieto’s spouse to acquire outstanding shares of Grupo Cibest for an amount equivalent to the proceeds obtained from the liquidation of the 63,736 units in the institutional investment fund managed by Protección S.A.

In addition, the Board of Directors authorized the son of director Andrés Felipe Mejía Cardona to acquire outstanding shares of Grupo Cibest for up to one hundred and fifty million Colombian pesos (COP $150,000,000) through a portfolio of the voluntary pension fund managed by Protección. This authorization was granted with the favorable vote of all directors, excluding Andrés Felipe Mejía, in accordance with the provisions of the Colombian Commercial Code.

These transactions will be carried out in compliance with the procedures established in the Good Governance Code for trading of Grupo Cibest shares by officers and directors, including adherence to blackout periods during which such officers and directors are prohibited from trading Grupo Cibest shares.



2

gc_logotipoxnegroxvertical.jpg

Contacts
Mauricio Botero Wolff
Catalina Tobón Rivera
Strategy and Financial VP
IR Director
Tel.: (57 604) 4040858
Tel.: (57 601) 4885950
ir@Grupocibest.com.co
ir@Grupocibest.com.co

3

FAQ

How much did ISRG's Q2 2025 revenue grow year over year?

Revenue rose 21% to $2.44 billion versus $2.01 billion in Q2 2024.

What is Intuitive Surgical's Q2 2025 diluted EPS?

Diluted earnings per share were $1.81, up 24% from $1.46 a year earlier.

How large is ISRG's current share-repurchase authorization?

The Board approved a $4 billion program; about $3.8 billion remains available.

What are the company’s cash and investment balances as of June 30 2025?

Combined cash, cash equivalents and investments total $9.53 billion.

Did gross margin improve in Q2 2025?

No. Gross margin fell to 66.3% from 68.3% in Q2 2024, reflecting product mix and cost factors.

What is the status of major litigation against ISRG?

Product liability and antitrust cases remain pending; no material new accruals were recorded this quarter.
Grupo Cibest S.A.

NYSE:CIB

CIB Rankings

CIB Latest News

CIB Latest SEC Filings

CIB Stock Data

10.74B
240.46M
23.57%
0.18%
Banks - Regional
Financial Services
Link
Colombia
Medellín